Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells

Journal of Immunotherapy

Volumn 37, Issue 1, 2014, Pages 8-15

  Hollevoet, Kevin ^a   Antignani, Antonella ^a   Fitzgerald, David J ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BH3 mimetic; Immunotoxin; Mesothelin; Pancreatic cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BCL2 RELATED PROTEIN A1; FURIN; IMMUNOTOXIN; IMMUNOTOXIN KLM1; IMMUNOTOXIN LMB2; IMMUNOTOXIN SS1P; MESOTHELIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFICACY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIPHENYL COMPOUNDS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GPI-LINKED PROTEINS; HUMANS; IMMUNOTOXINS; NITROPHENOLS; PANCREATIC NEOPLASMS; PIPERAZINES; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84890948033     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000010     Document Type: Article

References (35)

1. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;13: 607-620.
2. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6: 559-565. (Pubitemid 43980544)
3. Weldon JE, Pastan I. A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011;278: 4683-4700.
4. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93: 136-140. (Pubitemid 26041483)
5. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27: 1418-1428. (Pubitemid 37315193)
6. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7: 3862-3868. (Pubitemid 34044602)
7. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13: 5144-5149. (Pubitemid 47502082)
8. Kreitman RJ, Hassan R, FitzGerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15: 5274-5279.
9. Li Q, Verschraegen CF, Mendoza J, et al. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv) PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res. 2004; 24: 1327-1335. (Pubitemid 38954646)
10. Du X, Xiang L, Mackall C, et al. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL receptor 2 agonist antibody. Clin Cancer Res. 2011;17: 5926-5934.
11. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008; 9: 47-59.
12. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8: 782-798.
13. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435: 677-681. (Pubitemid 40825512)
14. Vogler M, Dinsdale D, Dyer MJ, et al. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16: 360-367.
15. Letai A. Restoring cancer's death sentence. Cancer Cell. 2006;10: 343-345. (Pubitemid 44693475)
16. Adams KW, Cooper GM. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem. 2007; 282: 6192-6200. (Pubitemid 47100899)
17. Du X, Youle RJ, FitzGerald DJ, et al. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol. 2010;30: 3444-3452.
18. Traini R, Ben-Josef G, Pastrana DV, et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther. 2010;9: 2007-2015.
19. Risberg K, Fodstad O, Andersson Y. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One. 2011;6:e24012.
20. Mattoo AR, Fitzgerald DJ. Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines. Int J Cancer. 2013;132: 978-987.
21. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol. 2004;248: 503-518.
22. Kimura Y, Kobari M, Yusa T, et al. Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1). Int J Pancreatol. 1996;20: 43-50. (Pubitemid 26292147)
23. Onda M, Willingham M, Nagata S, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting,Western blotting, and ELISA. Clin Cancer Res. 2005;11: 5840-5846. (Pubitemid 41170311)
24. Rasband WS. ImageJ. Bethesda, MD: US National Institutes of Health; 1997-2012. Available at: http://rsbweb.nih.gov/ij/.
25. Kepp O, Galluzzi L, Lipinski M, et al. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011;10: 221-237.
26. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 1999;94: 3340-3348. (Pubitemid 29536127)
27. Du X, Beers R, Fitzgerald DJ, et al. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 2008;68: 6300-6305.
28. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008; 68: 2944-2951. (Pubitemid 351556295)
29. Olberding KE, Wang X, Zhu Y, et al. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Cancer Biol Ther. 2010;10: 918-929.
30. Yamaguchi R, Janssen E, Perkins G, et al. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One. 2011;6:e24102.
31. Chiron MF, Fryling CM, FitzGerald D. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem. 1997;272: 31707-31711. (Pubitemid 28013318)
32. Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Molecular Cell. 2010;37: 299-310.
33. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8: 121-132. (Pubitemid 351161322)
34. Wei H, Xiang L, Wayne AS, et al. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci U S A. 2012;109: 6898-6903.
35. Tortorella LL, Pipalia NH, Mukherjee S, et al. Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary. PLoS One. 2012;7:e47320.